Skip to main content

Table 3 Breast Cancer Related Cumulative Charges by Receptor Status and Charge Type

From: Estimation of healthcare‐related charges in women with BRCA mutations and breast cancer

Health care charges ($US) HER2 + 
ER+/PR+/HER2 + or ER-/PR-/HER2 + 
n = 142
HER2-
TNBC or ER+/PR+/HER2-
n = 521
HER2 + vs. HER2-
Mean
(SD)
Median
(IQR)
Mean
(SD)
Median
(IQR)
p-value
Facilities/ Technical 36,523
(28,082)
34,647
(39,683)
28,707
(26,418)
24,207
(32,460)
0.00
Physician/ Professional 18,191
(14,195)
16,138
(17,411)
15,648
(12,973)
12,577
(17,458)
0.04
Pharmacy 101,145
(94,243)
10,1374
(147,132)
25,529
(39,646)
7,303
(42,884)
< 0.0001
Total Anticancer Treatment 82,890
(81,269)
81,783
(127,300)
7,929
(21,782)
1,364
(6,006)
< 0.0001
 Clinical Trial 96
(430)
0
(0)
39
(199)
0
(0)
0.26
 Chemotherapy 10,443
(15,582)
4,417
(14,415)
6,222
(13,642)
1,074
(5,461)
< 0.0001
 Hormonal Therapy 496
(3,889)
0
(0)
935
(5,660)
0
(0)
0.46
 Biologic Therapy 71,855
(72,075)
6,5471
(117,006)
732
(12,692)
0
(0)
< 0.0001
Other Medication(s) 18,255
(21,988)
6,517
(29,473)
17,600
(25,321)
2,953
(29,228)
0.02
  1. SD Standard deviation, IQR Interquartile range